Ryan CW - Search Results

1

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.

Ryan CW, Vokes EE, Vogelzang NJ, Janisch L, Kobayashi K, Ratain MJ. Ryan CW, et al. Cancer Chemother Pharmacol. 2002 Jul;50(1):1-5. doi: 10.1007/s00280-002-0458-y. Epub 2002 May 9. Cancer Chemother Pharmacol. 2002. PMID: 12111104 Clinical Trial.

2

A review of chemotherapy trials for malignant mesothelioma.

Ryan CW, Herndon J, Vogelzang NJ. Ryan CW, et al. Chest. 1998 Jan;113(1 Suppl):66S-73S. doi: 10.1378/chest.113.1_supplement.66s. Chest. 1998. PMID: 9438693 Review.

3

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.

Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Ryan CW, et al. Cancer. 2000 Mar 15;88(6):1317-24. Cancer. 2000. PMID: 10717612 Clinical Trial.

4

CI-980 in advanced melanoma and hormone refractory prostate cancer.

Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. Ryan CW, et al. Invest New Drugs. 2000 May;18(2):187-91. doi: 10.1023/a:1006382014403. Invest New Drugs. 2000. PMID: 10857996 Clinical Trial.

5

Gemcitabine in the treatment of bladder cancer.

Ryan CW, Vogelzang NJ. Ryan CW, et al. Expert Opin Pharmacother. 2000 Mar;1(3):547-53. doi: 10.1517/14656566.1.3.547. Expert Opin Pharmacother. 2000. PMID: 11249537 Review.

6

Docetaxel and exisulind in hormone-refractory prostate cancer.

Ryan CW, Stadler WM, Vogelzang NJ. Ryan CW, et al. Semin Oncol. 2001 Aug;28(4 Suppl 15):56-61. doi: 10.1016/s0093-7754(01)90156-3. Semin Oncol. 2001. PMID: 11685730 Clinical Trial.

7

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer.

Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM. Park DK, et al. Among authors: ryan cw. Cancer Chemother Pharmacol. 2002 Aug;50(2):160-2. doi: 10.1007/s00280-002-0473-z. Epub 2002 Jul 5. Cancer Chemother Pharmacol. 2002. PMID: 12172983 Clinical Trial.

8

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.

Ryan CW, Vogelzang NJ, Stadler WM. Ryan CW, et al. Cancer. 2002 May 15;94(10):2602-9. doi: 10.1002/cncr.10528. Cancer. 2002. PMID: 12173327 Free article. Clinical Trial.

9

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Stadler WM, et al. Among authors: ryan cw. J Urol. 2003 Oct;170(4 Pt 1):1141-5. doi: 10.1097/01.ju.0000086829.74971.4a. J Urol. 2003. PMID: 14501711 Clinical Trial.

10

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Davis NB, et al. Among authors: ryan cw. J Clin Oncol. 2004 Jan 1;22(1):115-9. doi: 10.1200/JCO.2004.07.165. J Clin Oncol. 2004. PMID: 14701773 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters